Filling of High-Concentration Monoclonal Antibody Formulations into Pre-Filled Syringes: Filling Parameter Investigation and Optimization

References

1. 1.↵
   1. Romacker M.,
   2. Schoenknecht T.,
   3. Forster R.

   The rise of prefilled syringes from niche product to primary container of choice: a short history. ONdrugDelivery 2008, 4, 4–5. Available at http://www.ondrugdelivery.com/publications/prefilled_syringes_2008.pdf; accessed March 5, 2013.

   OpenUrl
2. 2.↵
   1. Stockwin L. H.,
   2. Holmes S.

   Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther. 2003, 3 (7), 1133–1152.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Shire S. J.,
   2. Shahrokh Z.,
   3. Liu J.

   Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93 (6), 1390–1402.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Overcashier D. E.,
   2. Chan E. K.,
   3. Hsu C. C.

   Technical considerations in the development of prefilled syringes for protein products. Am. Pharm. Rev. 2006, 9(7), 77–83.

   OpenUrl
5. 5.↵
   1. Chana E.,
   2. Maa Y.-F.,
   3. Overcashier D. E.

   ; Manufacturing consideration in developing a prefilled syringe – investigating the effect of headspace pressure. Pharm. Rev. 2012, 15(3), 1–5.

   OpenUrl
6. 6.↵
   1. Kanai S.,
   2. Liu J.,
   3. Patapoff T. W.,
   4. Shire S. J.

   Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interactions that impact solution viscosity. J. Pharm. Sci. 2005, 97(10), 4219–4227.

   OpenUrl
7. 7.↵
   1. Alford J. R.,
   2. Kendrick B. S.,
   3. Carpenter J. F.,
   4. Randolph T. W.

   High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J. Pharm. Sci. 2008, 97(8), 3005–3021.

   OpenUrlPubMed
8. 8.↵
   1. Salinas B. A.,
   2. Sathish H. A.,
   3. Bishop S. M.,
   4. Harn N.,
   5. Carpenter J. F.,
   6. Randolph T. W.

   Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J. Pharm. Sci. 2010, 99(1), 82–93.

   OpenUrlPubMed
9. 9.↵
   1. Sukumar M.,
   2. Doyle B. L.,
   3. Combs J. L.,
   4. Pekar A. H.

   Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 2004, 21(7), 1087–1093.

   OpenUrlPubMed
10. 10.↵
    1. Tyagi A. K.,
    2. Randolph T. W.,
    3. Dong A.,
    4. Maloney K. M.,
    5. Hitscherich C. Jr..,
    6. Carpenter J. F.

    IgG particle formation during pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J. Pharm. Sci. 2009, 98(1), 94–104.

    OpenUrlPubMed
11. 11.↵
    1. Thomas C. R.,
    2. Geer D.

    Effects of shear on proteins in solution. Biotechnology Lett. 2010, 33(3), 443–456.

    OpenUrl
12. 12.↵
    1. Deegan R. D.,
    2. Bakajin O.,
    3. Dupont T. F.,
    4. Huber G.,
    5. Nagek S. R.,
    6. Witten T. A.

    Capillary flow as the cause of ring stains from dried liquid drops. Nature 1997, 389(6653), 827–829.

    OpenUrlCrossRefWeb of Science